US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

BIOCARDIA INC

0.0061

0.0000

Volume:- -

Turnover:- -

Market Cap:41.02K

PE:0.00

High:0.0061

Open:0.0061

Low:0.0061

Close:0.0061

52wk High:0.0061

52wk Low:0.0061

Shares:6.73M

Float Shares:3.13M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.1995

EPS(LYR):-3.2801

ROE:-829.13%

ROA:-176.83%

PB:0.05

PE(LYR):0.00

Loading ...

Overview Company News Filings

Biotech Alert: Searches spiking for these stocks today

BioCardia Announces First Patient in Phase 3 Randomized Controlled Double-Blind CardiAMP HF II Clinical Trial of the Company’s Lead Cell Therapy for Treatment of Heart Failure

BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study

BioCardia Inc (BCDA) Q4 2024 Earnings Call Highlights: Strategic Cost Reductions and Promising ...

BioCardia’s Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today

BioCardia Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.

BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF)

BioCardia upgraded to Buy from Neutral at Alliance Global Partners

BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions

BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure

BioCardia Third Quarter 2024 Earnings: US$0.61 loss per share (vs US$1.79 loss in 3Q 2023)

Simply Wall St.

BioCardia Inc (BCDA) Q3 2024 Earnings Call Highlights: Breakthroughs and Challenges in Cardiac ...

BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results

BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BCDAW/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BCDAW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCDAW\",,,,,undefined,":{"symbol":"BCDAW","market":"US","secType":"STK","nameCN":"BIOCARDIA INC","latestPrice":0.0061,"timestamp":1756497600000,"preClose":0.0061,"halted":0,"volume":0,"delay":0,"floatShares":3133364,"shares":6725025,"eps":-3.199549,"marketStatus":"Market Closed","change":0,"latestTime":"08-29 16:00:00 EDT","open":0.0061,"high":0.0061,"low":0.0061,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-3.199549,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1756800000000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":0.0061,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCDAW\",,,,,undefined,":{"symbol":"BCDAW","floatShares":3133364,"roa":"-176.83%","roe":"-829.13%","lyrEps":-3.280116,"shares":6725025,"dividePrice":0,"high":0.0061,"amplitude":0,"preClose":0.0061,"low":0.0061,"week52Low":0.0061,"pbRate":"0.05","week52High":0.0061,"institutionHeld":0.0108,"latestPrice":0.0061,"eps":-3.199549,"divideRate":0,"volume":0,"delay":0,"ttmEps":-3.199549,"open":0.0061,"prevYearClose":0.0061,"prevWeekClose":0.0061,"prevMonthClose":0.0061,"prevQuarterClose":0.0061,"fiveDayClose":0.0061,"twentyDayClose":0.0061,"sixtyDayClose":0.0061},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BCDAW\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-11","symbol":"BCDAW","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754884800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-08-05","symbol":"BCDAW","reason":null,"defaultRemindTime":1722864600000,"announcedDate":"2024-08-02","type":"delisting","dateTimestamp":1722830400000},{"market":"US","date":"2022-08-10","symbol":"BCDAW","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1660104000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2022-05-11","symbol":"BCDAW","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1652241600000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2022-03-29","symbol":"BCDAW","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1648526400000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BCDAW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BCDAW\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BCDAW\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2532000582","title":"Biotech Alert: Searches spiking for these stocks today","url":"https://stock-news.laohu8.com/highlight/detail?id=2532000582","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532000582?lang=en_us&edition=fundamental","pubTime":"2025-05-02 00:15","pubTimestamp":1746116123,"startTime":"0","endTime":"0","summary":"These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:. Discover companies with rock-solid fundamentals in  TipRanks' Smart Value Newsletter.Receive undervalued stocks, resilient to market uncertainty,  delivered straight to your inbox.Tevogen Bio Holdings , 332% surge in interest. Pipeline and key clinical candidates for these companies:. Galmed is a clinical stage biopharmaceutical company focused on the development of Aramchol for liver and fibro-inflammatory diseases. The company has focused almost exclusively on developing Aramchol for the treatment of noncirrhotic nonalcoholic steatohepatitis, or NASH, and are currently developing Aramchol for Primary Sclerosing Cholangitis, or PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of liver disease.CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commer","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/biotech-alert-searches-spiking-stocks-161523387.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biotech-alert-searches-spiking-stocks-161523387.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NVS","GLMD","IE0002141913.USD","TVGN","BK4539","BCDA","BCDAW","CGON","BK4588","BK4585","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","LU0208291251.USD","BK4578","LU0320765489.SGD","TVGNW","IE0009355771.USD","CMMB","RGLS","BK4007","BK4532","SWTX","LU0070302665.USD","IE00B4R5TH58.HKD","SNTI","LU0211331839.USD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","BK4139","MKKGY"],"gpt_icon":0},{"id":"2532169003","title":"BioCardia Announces First Patient in Phase 3 Randomized Controlled Double-Blind CardiAMP HF II Clinical Trial of the Company’s Lead Cell Therapy for Treatment of Heart Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2532169003","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532169003?lang=en_us&edition=fundamental","pubTime":"2025-05-01 21:00","pubTimestamp":1746104400,"startTime":"0","endTime":"0","summary":"SUNNYVALE, Calif., May 01, 2025  -- BioCardia, Inc. [NASDAQ: BCDA],a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the first patient enrolled in the Phase III randomized procedure placebo-controlled double-blind CardiAMP HF II clinical trial of the Company’s lead autologous cell therapy program for the treatment of heart failure at BayCare Morton PlantHospital in Clearwater, Florida.“We are thankful for the BayCare Morton Plant team led by Dr. Miller and Dr. Sharma as well as the many other world-class clinical teams engaged in the CardiAMP cell therapy trials,” said Peter Altman, PhD, BioCardia President and Chief Executive Officer. “We are preparing regulatory submissions in Japan and the USA intended to seek separate approvals of the CardiAMP cell therapy and Helix biotherapeutic delivery platform based on our existing TABMMI1, TAC-HFT2,3, and CardiAMP HF4 clinical data. The CardiAMP HF II trial is","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biocardia-announces-first-patient-phase-130000921.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","HF","LU2637428348.USD","CMS","BCDAW","BK4139","BCDA","LU1894683348.USD","LU2500361329.USD","BK4585","BK4208","LU2346227817.USD","LU1894683264.USD"],"gpt_icon":0},{"id":"2526666470","title":"BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2526666470","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526666470?lang=en_us&edition=fundamental","pubTime":"2025-04-11 21:15","pubTimestamp":1744377300,"startTime":"0","endTime":"0","summary":"CardiAMP HF II is Evaluating the CardiAMP Cell Therapy Product for Treating Patients with Ischemic Heart Failure of Reduced Ejection Fraction and Elevated Markers of Cardiac Stress. Dr. Arshed Quyyumi, Professor of Medicine, Division of Cardiology, Department of Medicine, Emory University School of Medicine, and Co-Director of the Emory Clinical Cardiovascular Research Institute to Serve as Principal Investigator. SUNNYVALE, Calif., April 11, 2025  -- BioCardia, Inc.[Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that Emory University School of Medicine in Atlanta Georgia is now enrolling patients with ischemic heart failure in the Company’s ongoing pivotal Phase III CardiAMP HF II trial. Emory University joins esteemed clinical sites throughout the United States participating in the study.Heart failure of reduced ejection fraction  is a clinical condition in which the output of blood ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biocardia-initiates-patient-enrollment-emory-131500625.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1894683264.USD","BK4208","BCDAW","BK4585","BK4588","LU1894683348.USD","LU2637428348.USD","LU2500361329.USD","BCDA","HF","BK4139","CMS","LU2346227817.USD"],"gpt_icon":0},{"id":"2524015959","title":"BioCardia Inc (BCDA) Q4 2024 Earnings Call Highlights: Strategic Cost Reductions and Promising ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2524015959","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524015959?lang=en_us&edition=fundamental","pubTime":"2025-04-01 15:03","pubTimestamp":1743491003,"startTime":"0","endTime":"0","summary":"Total Expense: Decreased 35% year-over-year to $8.1 million in 2024 from $12.1 million in 2023.Research and Development Expense: Decreased 43% to $4.4 million in 2024 from $7.7 million in 2023.Selling, General and Administrative Expenses: Decreased 16% to $3.7 million in 2024 from $4.4 million in 2023.Net Loss: Decreased to $7.9 million in 2024 from $11.6 million in 2023.Net Cash Used in Operations: Approximately $8 million in 2024, down from approximately $10 million in 2023.Cash and Cash Equivalents: Ended the year with $2.4 million.GuruFocus has detected 7 Warning Signs with BCDA.For the complete transcript of the earnings call, please refer to the full earnings call transcript.BioCardia Inc  reported a significant reduction in mortality rates in their CardiAMP HF clinical trial, which is a positive outcome in a field where no current therapy reduces mortality.The CardiAMP HF trial showed a 47% relative risk reduction in heart death equivalents and a 16% relative risk reduction in m","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biocardia-inc-bcda-q4-2024-070323496.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BCDA","BCDAW"],"gpt_icon":0},{"id":"2524973473","title":"BioCardia’s Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2524973473","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524973473?lang=en_us&edition=fundamental","pubTime":"2025-04-01 01:39","pubTimestamp":1743442740,"startTime":"0","endTime":"0","summary":"SUNNYVALE, Calif., March 31, 2025  -- BioCardia, Inc.[Nasdaq: BCDA],a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today clarifies that two-year CardiAMP-HF results will be addressed in a conference call scheduled for today, Monday, March 31, 2025 at 4:30pm EDT. The press release earlier this morning incorrectly noted the call would be held at 4:30pm PDT.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biocardia-conference-call-today-monday-173900142.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BCDAW","BCDA","BK4139"],"gpt_icon":0},{"id":"2522527927","title":"BioCardia Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag","url":"https://stock-news.laohu8.com/highlight/detail?id=2522527927","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522527927?lang=en_us&edition=fundamental","pubTime":"2025-03-28 19:02","pubTimestamp":1743159768,"startTime":"0","endTime":"0","summary":"AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.NasdaqCM:BCDA Earnings and Revenue History March 28th 2025. All figures shown in the chart above are for the trailing 12 month  period. Revenue missed analyst estimates by 37%. Earnings per share  exceeded analyst estimates by 6.8%.Looking ahead, revenue is forecast to grow 83% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.The company's shares are up 8.5% from a week ago.Be aware that  BioCardia is showing  7 warning signs in our investment analysis and 4 of those shouldn't be ignored...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biocardia-full-2024-earnings-eps-110248237.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BCDAW","BCDA"],"gpt_icon":0},{"id":"2511135540","title":"BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2511135540","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511135540?lang=en_us&edition=fundamental","pubTime":"2025-02-13 21:30","pubTimestamp":1739453400,"startTime":"0","endTime":"0","summary":"Focus on Patients with Elevated Markers of Heart Stress and Inflammation. Procedural enhancement using FDA Approved Morph DNA steerable guide for therapeutic delivery. SUNNYVALE, Calif., Feb. 13, 2025  -- BioCardia, Inc.[Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today completion of enrollment and dosing in the low dose cohort in its CardiALLO Allogeneic Mesenchymal Cell Therapy Phase I/II trial. The trial is designed to treat patients with ischemic heart failure of reduced ejection fraction  and is believed to be the world’s first prospective trial of allogeneic mesenchymal stem cells  intended for treating HFrEF patients having elevated markers of heart stress and systemic inflammation.The “off the shelf” mesenchymal stem cells utilized for the study treatment are believed to act by providing immunomodulatory benefits in inflammatory dise","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biocardia-reports-completion-low-dose-133000221.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4150","BK4139","BK4575","BCDAW","MSC","BCDA"],"gpt_icon":0},{"id":"2507952989","title":"BioCardia upgraded to Buy from Neutral at Alliance Global Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2507952989","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507952989?lang=en_us&edition=fundamental","pubTime":"2025-01-31 20:16","pubTimestamp":1738325769,"startTime":"0","endTime":"0","summary":"Alliance Global Partners analyst James Molloy upgraded BioCardia  to Buy from Neutral with a $6 price target The company recently announced multiple clinical updates regarding its lead CardiAMP cell therapy platform BCDA-01, which has completed the last patient follow-up and should report final 24-month data in Q1, the analyst tells investors in a research note. The firm cites potential positive upcoming catalysts in Q1 and the stock’s “low current valuation” for the upgrade.Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.BioCardia announces results of its placebo-controlled CardiAMP HF Phase 3 study. BioCardia announces commercial availability of Morph DNA product family. BioCardia announces completion of consoltation with Japan’s PMDA","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/biocardia-upgraded-buy-neutral-alliance-121609365.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biocardia-upgraded-buy-neutral-alliance-121609365.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BCDA","BCDAW"],"gpt_icon":0},{"id":"2506370494","title":"BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions","url":"https://stock-news.laohu8.com/highlight/detail?id=2506370494","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506370494?lang=en_us&edition=fundamental","pubTime":"2025-01-27 22:15","pubTimestamp":1737987300,"startTime":"0","endTime":"0","summary":"SUNNYVALE, Calif., Jan. 27, 2025  -- BioCardia, Inc.[NASDAQ: BCDA] today announced that the results of its double-blind randomized placebo-controlled CardiAMP HF Phase 3 study have been accepted for presentation in a late-breaking symposium at the American College of Cardiology 2025 Scientific Sessions, taking place in Chicago, March 29-31, 2025.The American College of Cardiology Scientific Sessions meeting is one of the leading forums for the latest developments in clinical trials for cardiovascular disease. Attendees include experts from across the cardiovascular medical, pharmaceutical, biotechnology, and medical device communities who share a common goal of advancing treatment for cardiovascular disease.About BioCardiaBioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s biotherapeuti","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biocardia-announces-breaking-clinical-trial-141500681.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2637428348.USD","LU2346227817.USD","BCDAW","LU1894683264.USD","BCDA","LU1894683348.USD","BK4208","BK4117","CMS","BK4107","BK4139","BK4588","AFG","BK4585"],"gpt_icon":0},{"id":"2488196285","title":"BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2488196285","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488196285?lang=en_us&edition=fundamental","pubTime":"2024-12-04 21:30","pubTimestamp":1733319000,"startTime":"0","endTime":"0","summary":"Next PMDA Consultation after Review of CardiAMP HF Trial Data. “This most recent meeting with PMDA had several important outcomes,” said Peter Altman, Ph.D., BioCardia’s President and Chief Executive Officer.” First, PMDA has invited our next consultation after the submission of our final clinical data with two-year follow-up to review the sufficiency of evidence to support claims of safety and efficacy for the BCDA-01 program. Second, PMDA remains open to the results from the CardiAMP Heart Failure Trial and our previous trials being sufficient evidence for registering CardiAMP Cell Therapy System for patients with heart failure in Japan.”Dr. Altman continued, “We are working on data lock from our fully enrolled 125 patient CardiAMP Heart Failure Trial and anticipate final data will be available in the first quarter of 2025.”","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/BwoRPiuVsyL9bn0HQQmQTQ--~B/aD0zMDA7dz0xMzMzO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/64948509b7f9139e7048f9073e47bfbf","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/BwoRPiuVsyL9bn0HQQmQTQ--~B/aD0zMDA7dz0xMzMzO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/64948509b7f9139e7048f9073e47bfbf"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biocardia-announces-positive-consultation-japan-133000526.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BCDAW","LU2346227817.USD","BCDA","BK4585","LU1894683348.USD","LU2637428348.USD","CMS","BK4588","LU1894683264.USD","BK4208"],"gpt_icon":0},{"id":"2483519814","title":"BioCardia Third Quarter 2024 Earnings: US$0.61 loss per share (vs US$1.79 loss in 3Q 2023)","url":"https://stock-news.laohu8.com/highlight/detail?id=2483519814","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483519814?lang=en_us&edition=fundamental","pubTime":"2024-11-16 21:04","pubTimestamp":1731762285,"startTime":"0","endTime":"0","summary":"NasdaqCM:BCDA Earnings and Revenue History November 16th 2024. All figures shown in the chart above are for the trailing 12 month  period. Looking ahead, revenue is forecast to grow 94% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US.The company's shares are down 18% from a week ago.We should say that we've discovered 7 warning signs for BioCardia (6 are a bit unpleasant!) that you should be aware of before investing here.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biocardia-third-quarter-2024-earnings-130445792.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BCDAW","BCDA"],"gpt_icon":0},{"id":"2483843613","title":"BioCardia Inc (BCDA) Q3 2024 Earnings Call Highlights: Breakthroughs and Challenges in Cardiac ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2483843613","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483843613?lang=en_us&edition=fundamental","pubTime":"2024-11-14 15:13","pubTimestamp":1731568429,"startTime":"0","endTime":"0","summary":"For the complete transcript of the earnings call, please refer to the full earnings call transcript.BioCardia Inc  has received FDA breakthrough designation for its lead autologous cardiac cell therapy for heart failure, which is also reimbursed by Medicare and Medicaid.The company is conducting two active clinical trials for its cardiac cell therapy, with promising interim results showing improved survival and reduced major adverse cardiac events.The company successfully closed a $7.2 million public offering, ensuring compliance with Nasdaq's listing requirements and extending its financial runway.Research and development expenses have decreased significantly, reflecting efficient management and completion of enrollment in the cardiac heart failure one trial.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/HywZe.sRwdFFg1.Cdt56qA--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/60923920049f23264f07b5e44a14cc70","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/HywZe.sRwdFFg1.Cdt56qA--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/60923920049f23264f07b5e44a14cc70"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biocardia-inc-bcda-q3-2024-071349073.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BCDA","BCDAW"],"gpt_icon":1},{"id":"2483633448","title":"BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2483633448","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483633448?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:05","pubTimestamp":1731531900,"startTime":"0","endTime":"0","summary":"SUNNYVALE, Calif., Nov. 13, 2024  -- BioCardia, Inc.[Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the third quarter of 2024 and filed its quarterly report on Form 10-Q for the three and nine months ended September 30, 2024 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management’s formal remarks, there will be a question-and-answer session.CardiAMP autologous cell therapy in ischemic heart failure of reduced ejection fraction . The FDA approved the 510 of our steerable introducer sheath product family for cardiac, aorto-ostial, and peripheral clinical indications in August 2024.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/BwoRPiuVsyL9bn0HQQmQTQ--~B/aD0zMDA7dz0xMzMzO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/64948509b7f9139e7048f9073e47bfbf","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/BwoRPiuVsyL9bn0HQQmQTQ--~B/aD0zMDA7dz0xMzMzO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/64948509b7f9139e7048f9073e47bfbf"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biocardia-reports-third-quarter-2024-210500725.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BCDAW","BK4139","BCDA"],"gpt_icon":0},{"id":"2481703326","title":"BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2481703326","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481703326?lang=en_us&edition=fundamental","pubTime":"2024-11-06 20:00","pubTimestamp":1730894400,"startTime":"0","endTime":"0","summary":"SUNNYVALE, Calif., Nov. 06, 2024  -- BioCardia, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three and nine months ended September 30, 2024 by conference call on Wednesday, November 13, 2024 at 4:30 PM ET. Following management’s formal remarks, there will be a question-and-answer session.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/BwoRPiuVsyL9bn0HQQmQTQ--~B/aD0zMDA7dz0xMzMzO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/64948509b7f9139e7048f9073e47bfbf","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/BwoRPiuVsyL9bn0HQQmQTQ--~B/aD0zMDA7dz0xMzMzO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/64948509b7f9139e7048f9073e47bfbf"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biocardia-host-q3-2024-corporate-120000027.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HST","BK4139","BK4585","BCDA","BK4181","BCDAW","BK4588","BK4218"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":14,"code":"91000000","status":"200"}]}}